PSMA-positive

Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)

ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...